In Vitro Properties and Virulence of Contemporary Recombinant Influenza B Viruses Harboring Mutations of Cross-Resistance to Neuraminidase Inhibitors

Three neuraminidase inhibitors (NAIs: Oseltamivir, zanamivir and peramivir) are currently approved in many countries for the treatment of influenza A and B infections. The emergence of influenza B viruses (IBVs) containing mutations of cross-resistance to these NAIs constitutes a serious clinical th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fage, Clément, Abed, Yacine, Checkmahomed, Liva, Venable, Marie-Christine, Boivin, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357004/
https://www.ncbi.nlm.nih.gov/pubmed/30583488
http://dx.doi.org/10.3390/v11010006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357004/
https://www.ncbi.nlm.nih.gov/pubmed/30583488
http://dx.doi.org/10.3390/v11010006

Ejemplares similares